StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.03−0.03 (-2.83%)

Close on Nov 18, 2026Market cap $103.35MP/E –Yield –

Cellectis shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Cellectis's shares outstanding was 101M at Jun 30, 2026. For fiscal 2025 it was 100M, up 10.7% from the year before. Over ten years it grew 11.4% a year on average. The highest annual figure on record is 100M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 2025100M+10.7%
FY2024Dec 31, 202491M+58.9%
FY2023Dec 31, 202357M+25.2%
FY2022Dec 31, 202246M+1.6%
FY2021Dec 31, 202145M+5.5%
FY2020Dec 31, 202043M+0.1%
FY2019Dec 31, 201942M+4.1%
FY2018Dec 31, 201841M+14.2%
FY2017Dec 31, 201736M+1.2%
FY2016Dec 31, 201635M+3.3%
FY2015Dec 31, 201534M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026101M+121.2%
Q2 FY2025Jun 30, 2025100M+120.6%
Q2 FY2024Jun 30, 202490M+111.6%
Q2 FY2023Jun 30, 202356M+31.0%
Q2 FY2022Jun 30, 202246M–
Q2 FY2021Jun 30, 202145M–
Q2 FY2020Jun 30, 202042M–
Q2 FY2019Jun 30, 201942M–

More Cellectis figures

See a number that looks wrong?